Enhancing Access to Lipid-Lowering Therapies and Optimizing Cholesterol Management in Very High-Risk Patients with ASCVD : Episode 3

Opinion

Video

April 30, 2024

Comparing the ACC/AHA and ESC/EAS Cholesterol Management Guidelines

Author(s):

Craig Beavers, PharmD, FACC, FAHA, FCCP, BCCP, BCPSAQ Cardiology, CACP,Kate Cabral, PharmD, BCCP, FACC, FCCP

The panel compares the ACC/AHA cholesterol guidelines with the ESC/EAS guidelines and provides thoughts on how educational initiatives can be improved to increase familiarity and implementation.

EP: 1.How Often Do Patients with ASCVD Achieve Target LDL-C?

EP: 2.Gaps Between Guidelines and Clinical Practice Patterns in ASCVD

Now Viewing

EP: 3.Comparing the ACC/AHA and ESC/EAS Cholesterol Management Guidelines

EP: 4.Key Barriers in Implementing Guideline-Directed Cholesterol Treatment

EP: 5.Evaluating Non-Statin Lipid-Lowering Therapies in ASCVD

EP: 6.Clinical Efficacy of Non-Statin Treatment Options in ASCVD

EP: 7.Non-Statin Therapies: Cost Effectiveness and Clinical Evidence Gaps

EP: 8.Persistence and Discontinuation Rates for Non-Statin Therapies in ASCVD

EP: 9.The Role of Pharmacists in Treating Very High-Risk ASCVD

EP: 10.Valuable Metrics and Improving Adherence in Patients With ASCVD

EP: 11.Successful Collaborative Care Strategies for Pharmacists

Related Content

FDA approval stamp for chenodiol -- Image credit: Olivier Le Moal | stock.adobe.com

Published: February 21st 2025 | Updated: February 21st 2025

Chenodiol, First Treatment for Cerebrotendinous Xanthomatosis, Receives FDA Approval

Gillian McGovern, Associate Editor

Doctor using stethoscope take a tap on the patient's arm and pressing pressure gauge button

February 20th 2025

Fluctuating Cholesterol Over Time Associated With Dementia Risk in Older Adults

Luke Halpern, Assistant Editor

Clogged arteries, Cholesterol plaque in the artery

February 13th 2025

FDA Accepts BLA for Lerodalcibep, a Novel Agent to Lower LDL Cholesterol in Atherosclerotic Cardiovascular Disease

Luke Halpern, Assistant Editor

Partly blocked vessel in high level of LDL (bad cholesterol) lipoprotein – isometric view 3d illustration

February 5th 2025

Study: Mechanisms Impacting LDL-C Are Inversely Associated With Type 2 Diabetes Risk

Luke Halpern, Assistant Editor

Stroke is also known to be driven by hypertension, diabetes, and dyslipidemia. | Image Credit: peterschreiber.media | stock.adobe.com

February 4th 2025

Findings Suggest Hemoglobin A1c, HDL-C Associated With Increased Risk of Stroke

Ashley Gallagher, Editor

Chronic Obstructive Pulmonary Disease, Cholesterol, ApoA-I | Image Credit: surasak | stock.adobe.com

January 28th 2025

Investigators Find Causal Link Between Apolipoprotein A-I and COPD

Ashley Gallagher, Editor

Related Content

Published: February 21st 2025 | Updated: February 21st 2025

Chenodiol, First Treatment for Cerebrotendinous Xanthomatosis, Receives FDA Approval

Gillian McGovern, Associate Editor

February 20th 2025

Fluctuating Cholesterol Over Time Associated With Dementia Risk in Older Adults

Luke Halpern, Assistant Editor

February 13th 2025

FDA Accepts BLA for Lerodalcibep, a Novel Agent to Lower LDL Cholesterol in Atherosclerotic Cardiovascular Disease

Luke Halpern, Assistant Editor

February 5th 2025

Study: Mechanisms Impacting LDL-C Are Inversely Associated With Type 2 Diabetes Risk

Luke Halpern, Assistant Editor

February 4th 2025

Findings Suggest Hemoglobin A1c, HDL-C Associated With Increased Risk of Stroke

Ashley Gallagher, Editor

January 28th 2025

Investigators Find Causal Link Between Apolipoprotein A-I and COPD

Ashley Gallagher, Editor